I am an organic chemist and pharmacologist. I work with pharmaceutical, nutraceutical and biotech companies on the parts of a project where being approximately right is expensive: what a molecule does at its target, whether a formulation survives contact with a production line, and whether a claim is actually supported by the data cited for it.
I work from primary sources, and I separate what a paper demonstrates from what it is assumed to demonstrate. Most costly decisions are made in that gap.
Four lanes. Engagements usually cross two of them, because a molecular question rarely stays molecular once a production line is involved.
| Area | What I deliver | Usual format |
|---|---|---|
| Molecular design & preclinical reasoning | ||
| Drug design | QSAR, CoMFA and in-silico assessment of a scaffold or analogue series; what the structure predicts and where the prediction stops being trustworthy. | Written assessment |
| Structure–activity interpretation | Reading an analogue series for target engagement, selectivity and the liabilities that travel with a substituent. | Written assessment |
| Pharmacodynamics & pharmacokinetics | Receptor profile, mechanism, ADME reasoning, and the interaction surface a compound brings with it. | Written assessment or review call |
| Formulation & manufacturing | ||
| Dosage-form design | Capsules, modified-release and injectable forms: excipient rationale, release behaviour, stability exposure. | Design document |
| Active ingredients | API specification, supplier documentation review, identity and purity criteria, and what a certificate of analysis does not tell you. | Specification & review memo |
| Production line design | GMP-compliant line and process layout, from unit operations to the flows and segregation the standard expects. | Design document |
| Sourcing & import | ||
| China → EU supply | Sourcing routes, supplier qualification, documentation and import pathway for raw materials and actives. | Advisory, per shipment or per programme |
| Evidence & claims | ||
| Claim auditing | Every claim on a product or in a dossier traced to its primary source, graded by evidence level, with the unsupported ones named. Superlatives get attacked separately from the facts they sit on: the fact usually survives, the superlative often does not. | Audit memo, claim by claim |
| Performance & cognition pharmacology | Nootropics and performance compounds: mechanism, evidence grading, and the rationale (or absence of one) behind a combination. | Written assessment or training session |
| Literature & competitive reading | What the field actually published this quarter, separated from what was announced about it. | Briefing, one-off or recurring |
Clients are not named, by agreement. The figures are as delivered.
Working language: English or Italian. Remote by default; on site in Switzerland and northern Italy where a line or a lab actually has to be seen.
Organic chemist, pharmacologist and drug designer. Sciences Pharmaceutiques at the École de Pharmacie Genève–Lausanne, a five-year programme completed in 2017, followed by postgraduate work in drug design and new psychoactive substances at the University of Pavia. Independent practice from Lugano since 2017, across molecular design, formulation and manufacturing.
Since 2013 I have also been an external scientific consultant to the European drugs agency — EMCDDA, now EUDA — and to the CFSRE, on the early identification and technical profiling of compounds emerging on the international market, including the first signals of the synthetic opioids.
Stated up front, because a consultant who is vague about scope costs more than one who is narrow about it.
Direct
For a scoping call, book a slot directly. Tell me the sector and the question in one paragraph; that is enough for me to prepare.
Book a scoping callOr write from here
Professional notice. Alessio Rossini is not a medical doctor and does not substitute for one. Consulting output is scientific and technical advice; it is not medical advice, diagnosis or treatment, and it does not constitute regulatory certification. Responsibility for commercial, clinical and regulatory decisions remains with the client.